Besides immunotherapy, treatment with BRAF(/MEK) inhibitors should be considered in metastatic BRAF-mutated conjunctival melanoma and can even be considered in the (neo)adjuvant setting. Here, MAP2K7 is linked to malignant conjunctival melanoma.